Insider Selling: Insmed Incorporated (NASDAQ:INSM) Insider Sells 4,407 Shares of Stock

Insmed Incorporated (NASDAQ:INSM) insider Michael Alexander Smith sold 4,407 shares of the company’s stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $67.81, for a total value of $298,838.67. Following the completion of the transaction, the insider now directly owns 92,203 shares in the company, valued at approximately $6,252,285.43. The trade was a 4.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Michael Alexander Smith also recently made the following trade(s):

• On Wednesday, May 14th, Michael Alexander Smith sold 409 shares of Insmed stock. The shares were sold at an average price of $65.61, for a total value of $26,834.49.

Insmed Trading Up 1.3%

INSM stock opened at $68.12 on Friday. The company’s 50-day simple moving average is $71.57 and its 200-day simple moving average is $73.10. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $84.91. The firm has a market cap of $12.41 billion, a P/E ratio of -12.19 and a beta of 0.84.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The firm had revenue of $92.82 million for the quarter, compared to analysts’ expectations of $91.63 million. During the same period in the previous year, the company earned ($1.06) earnings per share. The company’s revenue was up 22.9% compared to the same quarter last year. As a group, equities analysts forecast that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on INSM shares. Guggenheim reissued a “buy” rating and issued a $101.00 target price on shares of Insmed in a research report on Tuesday, February 25th. Morgan Stanley upped their price target on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Insmed in a report on Wednesday, February 19th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $100.00 price target on shares of Insmed in a report on Wednesday, March 19th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $90.00 price target on shares of Insmed in a report on Monday, May 12th. One equities research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Insmed presently has a consensus rating of “Moderate Buy” and a consensus target price of $94.63.

Institutional Investors Weigh In On Insmed

Several hedge funds have recently modified their holdings of the company. Woodline Partners LP boosted its stake in shares of Insmed by 53.3% during the 1st quarter. Woodline Partners LP now owns 248,770 shares of the biopharmaceutical company’s stock worth $18,979,000 after acquiring an additional 86,540 shares in the last quarter. Caxton Associates LLP purchased a new position in Insmed in the 1st quarter valued at about $441,000. Parkman Healthcare Partners LLC lifted its stake in Insmed by 6.3% in the 1st quarter. Parkman Healthcare Partners LLC now owns 37,901 shares of the biopharmaceutical company’s stock valued at $2,891,000 after buying an additional 2,233 shares in the last quarter. NWI Management LP lifted its stake in Insmed by 61.3% in the 1st quarter. NWI Management LP now owns 450,000 shares of the biopharmaceutical company’s stock valued at $34,330,000 after buying an additional 171,000 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Insmed by 4.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 109,489 shares of the biopharmaceutical company’s stock valued at $8,364,000 after buying an additional 4,176 shares in the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.